Advertisement
Advertisement
ELUT
Elutia Inc. Class A Common Stock
0.85
USDSponsored
-0.03
-3.52%
Aug 07, 15:55 UTC -4
Closed
After-Market
0.72
-0.13
-15.76%
ELUT Earnings Reports
Positive Surprise Ratio
ELUT beat 8 of 23 last estimates.
35%
Next Report
Next Week
Date of Next Report
Aug 13, 2026
Estimate for Q2 26 (Revenue/ EPS)
$2.96M
/-$0.15
Implied change from Q1 26 (Revenue/ EPS)
-5.01%
/-11.76%
Implied change from Q2 25 (Revenue/ EPS)
-52.77%
/-34.78%
Elutia Inc. Class A Common Stock earnings per share and revenue
On May 14, 2026, ELUT reported earnings of -0.17 USD per share (EPS) for Q1 26, missing the estimate of -0.15 USD, resulting in a -11.11% surprise. Revenue reached 3.11 million, compared to an expected 3.06 million, with a 1.76% difference. The market reacted with a -0.96% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 4 analysts forecast an EPS of -0.15 USD, with revenue projected to reach 2.96 million USD, implying an decrease of -11.76% EPS, and decrease of -5.01% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Cytokinetics Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$1.67
Actual
-$1.50
Surprise
+10.35%
Celldex Therapeutics, Inc
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$1.07
Actual
-$0.94
Surprise
+12.79%
ANI Pharmaceuticals, Inc.
Report Date
Aug 07, 2026 For Q2 26
Estimate
$2.09
Actual
$2.21
Surprise
+5.69%
Zymeworks Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.46
Actual
-$0.62
Surprise
-32.31%
Intellia Therapeutics, Inc
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.81
Actual
-$0.80
Surprise
+1.86%
Monte Rosa Therapeutics, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.39
Actual
-$0.43
Surprise
-9.58%
CytomX Therapeutics, Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.07
Actual
-$0.09
Surprise
-13.78%
Verastem, Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.44
Actual
-$0.35
Surprise
+20.69%
ALX Oncology Holdings Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.14
Actual
-$0.13
Surprise
+11.08%
Arcturus Therapeutics Holdings Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$1.01
Actual
-$0.84
Surprise
+17.53%
FAQ
What were Elutia Inc. Class A Common Stock's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Elutia Inc. Class A Common Stock reported EPS of -$0.17, missing estimates by -11.11%, and revenue of $3.11M, 1.76% above expectations.
How did the market react to Elutia Inc. Class A Common Stock's Q1 2026 earnings?
The stock price moved down -0.96%, changed from $1.04 before the earnings release to $1.03 the day after.
When is Elutia Inc. Class A Common Stock expected to report next?
The next earning report is scheduled for Aug 13, 2026.
What are the forecasts for Elutia Inc. Class A Common Stock's next earnings report?
Based on 4
analysts, Elutia Inc. Class A Common Stock is expected to report EPS of -$0.15 and revenue of $2.96M for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement